PROJECT

Pharmacokinetics of Linezolid when administered along with other Second line anti-TB drugs in MDR-TB/Pre-XDR-TB Patients

Feb 2021 - Oct 2026

Objectives:

To develop and validate methods for the estimation of Linezolid (LZD) in plasma and saliva by HPLC. To study the pharmacokinetics of LZD and other second line anti-TB drugs in adult patients with Multi-drug resistant (MDR-TB) and pre-extensive drug resistant (pre-XDR) tuberculosis patients.

Study Overview:

Limited information is available on the pharmacokinetics (PK) of second-line drugs used in the treatment regimen of MDR-TB and Pre-XDR TB, particularly in the Indian context. Therefore, here we plan to undertake a pharmacokinetic study of LZD and other second-line anti-TB drugs used in the treatment of MDR-TB and Pre-XDR TB.

Study Approach:

The study involves laboratory analysis of plasma anti-TB drug measurements using HPLC.

Expected Public Health Impact:

This study will provide information on the pharmacokinetic profile of LZD in plasma and saliva in MDR-TB and pre-XDR patients in India. Saliva LZD concentrations may be used for therapeutic drug monitoring in patients with MDR-TB and pre-XDR TB